Blood Gene Transcript Analysis Diagnoses Bronchopulmonary NETs and Identifies Progressive Disease Abstract #1571

Introduction: Broncho-Pulmonary (BP) NETs are pulmonary neoplasms with indolent to aggressive behavior. Imaging, histology and biochemistry are limited in defining malignancy or progression
Aim(s): Assess the NETest in BPNET diagnosis and progressive disease delineation.
Materials and methods: BPNETs (n=36), controls (n=38) and cancers (n=38). Measurements were NETest (positive >14%) and specific gene “omic” analysis: growth factor signaling (GFS: N-Ras, K-Ras, BRaf, Raf1) and somatostatin receptor (SSR1,3,5) expression by qPCR; CgA by ELISA (normal <109ng/ml); disease status by imaging. Tumors were typical TC: n=14, atypical AC: n=22 and stable (SD n=18) or progressive disease (PD n=18). 55% AC were PD, 42% TC were PD. Clinico-histological groups were AC/SD or AC/PD; TC/SD or TC/PD by RECIST. Analysis by X2 tests and ROC-statistics.
Conference: 13th Annual ENETS conference (2016)
Category: Biomarkers
Presenting Author: Professor Mark Kidd
Keywords: PCR

To read results and conclusion, please login ...

Further abstracts you may be interested in

#2220 Validation of a Blood-Based Biomarker Test for the Diagnosis and Management of Bronchopulmonary Neuroendocrine Tumors
Introduction: There is currently no effective blood biomarker for lung neuroendocrine neoplasia diagnosis and management.
Conference: 15th Annual ENETS conference (2018)
Category: Non digestive NETs (bronchial, thymic, others) - diagnosis and therapy
Presenting Author: Professor Mark Kidd
#1883 Utility of a Circulating NET mRNA Gene Signature for Defining Bronchopulmonary Neuroendocrine Neoplasia and Evaluating Disease Progression
Introduction: Bronchopulmonary NETs (BPNETs) exhibit indolent to aggressive behavior. Imaging, histology and biochemistry are limited in accurately defining malignancy or progression. A blood based NET multigene test is effective in diagnosing GEP-NET progression and therapy response.
Conference: 14th Annual ENETS conference (2017)
Category: Non digestive NETs (bronchial, MTC pheochromocytoma) Pathology, grading, staging
Presenting Author: Professor Mark Kidd
Keywords: NET
#343 PCR Assessment of Carcinoid Lymph Node Metastasis CgA Transcript Outperforms Immunostaining, Tyramide Signal Amplification and H&E and Significantly Upstages Disease
Introduction: Accurate neuroendocrine tumor (NETs) staging is vital for determining therapeutic strategy. Sensitive techniques to facilitate identification of metastases (mets) are of critical clinical relevance.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Dr Mark Kidd
Authors: Lawrence B, Kenney B, Kidd M, Modlin I, ...
#212 Reduced MEN1 Gene Expression in Pulmonary Carcinoids Is Associated With Metastatic Disease
Introduction: Lung carcinoids are neuroendocrine tumors that can be classified as typical (TC) or atypical (AC) carcinoids. Previously, MEN-1 mutations and associated LOH of 11q13 have been implied in tumorigenesis.
Conference: 8th Annual ENETS Conference (2011)
Category: Basic
Presenting Author: MSc Dorian R.A. Swarts
#897 A Molecular Multi-Transcript Gene Blood Signature Significantly Outperforms Chromogranin A (CgA) in the Detection of Gut Neuroendocrine Tumors (NETs)
Introduction: A key issue in NET management is the need for a specific and sensitive biomarker to detect disease and assess treatment. CgA is widely utilized but has limitations.
Conference: 11th Annual ENETS Conference (2014)
Category: Biomarkers
Presenting Author: Professor Irvin M Modlin
Authors: Modlin I M, Kidd M, Drozdov I, Alaimo D, ...
Keywords: biomarker, CgA, NET, PCR